Elanco Animal Health (ELAN) has kicked off a phased launch of Befrena, an anti IL 31 monoclonal antibody injection for canine allergic and atopic dermatitis, giving investors fresh information on its pet dermatology portfolio.

Elanco's recent Befrena launch comes as momentum in the stock has picked up in the short term, with a 7 day share price return of 12.48% and a 1 month share price return of 8.26%, even though the 3 month share price return is down 9.17% and the 5 year total shareholder return is also down 31.49% after a very large 3 year total shareholder return of around 18x. This suggests recent trading reflects shifting expectations around future growth and risk rather than a simple continuation of the past trend.

If you are looking beyond pet health to see where else investors are finding growth stories, this could be a useful moment to check out 21 top founder-led companies

With Befrena expanding Elanco's pet dermatology offering, recent gains and a history of sharp swings leave a key question for investors: is the stock still trading at a discount, or is the market already pricing in future growth?

Most Popular Narrative: 16.6% Undervalued

Elanco's most followed narrative puts fair value at $28.77, above the last close of $23.98, and frames Befrena's launch within a broader re rating story.

Elanco anticipates an acceleration in organic constant currency revenue growth of 4% to 6%, driven by innovation and market expansion. This will positively impact revenue growth.

Want to see what sits behind that revenue ramp and margin shift assumptions? The narrative focuses on higher earnings, richer profitability, and a punchy future multiple.

Result: Fair Value of $28.77 (UNDERVALUED)

However, there is still a risk that foreign exchange headwinds or slower than expected uptake of new products like Zenrelia and Credelio Quattro could challenge this story.

Next Steps

With the narrative tilted toward optimism, it makes sense to pressure test the thesis yourself and move quickly while the information is fresh by reviewing the 4 key rewards

Looking for more investment ideas?

If you want more than a single stock story, broaden your watchlist now using focused screens that surface opportunities other investors might miss.

• Target potential mispricing by scanning for quality companies trading below their estimated worth with the 46 high quality undervalued stocks.
• Strengthen your portfolio’s foundation by zeroing in on companies with robust finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot lesser known opportunities before the crowd by running the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.